BioWorld Asia

Dec. 25, 2002

CAT Reaches Agreement Over Patents With MorphoSys, Crucell

LONDON - Peace has broken out in long-running wars over antibody phage display patents, with Cambridge Antibody Technology Group plc granting licenses to MorphoSys AG and Crucell NV, and all existing litigation between the companies being withdrawn.(BioWorld International) Read More

Germany, Other Countries Told To Strengthen Patent Protections

New Drug For Malaria Shows Promise In First Clinical Trial

CeNeS Licenses Addiction Product To Swiss Firm Addex

Berna Biotech, Samsung Win Vietnamese Vaccines Project

Swiss Authorities Deal Setback To IsoTis For Skin Treatment

European Commission Calls For Proposals For Research Program

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...